WuXi STA Changzhou site passes first FDA inspection7 May 2018
The integrated R&D and manufacturing facility is expecting more products to go into commercial production post approval.
STA Pharmaceutical's API R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the US FDA – with no Form 483s issued. This is the first time that WuXi STA’s Changzhou facility has been inspected by the FDA.
WuXi STA has already passed several inspections from the FDA at its API and advanced intermediate manufacturing facility in Shanghai, Jinshan and at its drug product manufacturing facility in Shanghai, Waigaoqiao free trade zone. WuXi STA is the first CMC platform (including both APIs and drug product) in China to have passed FDA inspection for new chemical entities. It is also the first CDMO in China that is approved to supply APIs and GMP intermediates for branded commercial drugs by regulatory agencies in the US, China, EU, Canada, Switzerland, Australia, and New Zealand.
The Changzhou facility – which opened in early 2016 and is situated on a site of 39 acres – has been designed to keep pace with the increasing demand WuXi STA is seeing from customers, as more products move into commercial production.
Currently, the facility employs more than 1000 people including 200 scientists, and has three plants in operation. The company will continue to add more than 300 scientists and seven multi-functional plants within the next 5 years. As a purpose-built facility, Changzhou offers an integrated one-site solution for partners to accelerate innovative APIs and advanced intermediates – from preclinical and clinical development through to global commercial launch.
“Quality is ingrained throughout our culture here at WuXi STA and one of our core competencies. The Changzhou facility passing its first FDA inspection, with no observations – or even written or verbal recommendations – is yet further proof of our commitment to the highest possible quality standards. It’s a point of great pride that we have an exemplary regulatory record, and evidence of the company’s ability to supply the U.S. market with innovative commercial APIs from the Changzhou site.” said Dr Minzhang Chen, CEO of WuXi STA.
“We are very proud of successfully passing FDA inspection once more,” commented Ms Mei Hao, Vice President of Quality at WuXi STA, “we will continue to strengthen our global quality systems to meet and surpass even the most stringent regulatory requirements. This ensures we provide the highest standard of quality services to our partners worldwide.”
New portable and ready-to-use upper respiratory drug delivery solution
11 Oct 2018
PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.Read more
CPhI Worldwide announces the winners of the 15th Pharma Awards
10 Oct 2018
17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.Read more
CMOs to benefit from double digit approvals for ADCs in the next 3 years
9 Oct 2018
Therapeutic ADC market expected to reach $4 billion by 2023.Read more
Micro-Sphere increases capsule filling capacity
8 Oct 2018
The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.Read more
Symbiosis secures FDA viral vector process approval
5 Oct 2018
Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.Read more
Three-way collaboration to advance gene therapy
4 Oct 2018
Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.Read more
New horizontal flow wrapping machine for hermetic packages
3 Oct 2018
Greater product protection thanks to reliable sealing technologies.Read more
Movement on the market reflected at CPhI Worldwide 2018
3 Oct 2018
Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.Read more
Niche CDMO confirms spray drying for highly potent drugs
1 Oct 2018
Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.Read more
Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions
1 Oct 2018
The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation